Last Updated: June 4, 2026

Claims for Patent: 10,434,147

✉ Email this page to a colleague

Summary for Patent: 10,434,147

Title:	Treatment type 2 diabetes mellitus patients
Abstract:	A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
Inventor(s):	Roy; Christine (Paris, FR), Souhami; Elisabeth (Paris, FR), Demil; Nacima (Paris, FR), Ye; Jenny (Bridgewater, NJ)
Assignee:	SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt, DE)
Application Number:	15/646,760
Patent Claims:	1. A method for improving glycemic control in a patient with type 2 diabetes mellitus comprising: administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical combination comprising lixisenatide and insulin glargine; wherein the patient has a body mass index (BMI).gtoreq.30 kg/m.sup.2 or has experienced a hypoglycemic event; wherein the patient's type 2 diabetes mellitus is not adequately controlled after treatment with basal insulin; and wherein the patient requires additional glycemic control without the increase in hypoglycemia and weight gain of prandial insulin. 2. The method of claim 1, wherein the patient's type 2 diabetes mellitus is not adequately controlled after treatment with basal insulin and metformin. 3. The method of claim 1, wherein the patient's type 2 diabetes mellitus is not adequately controlled after treatment with basal insulin and one to three oral anti-diabetic drugs (OADs). 4. The method of claim 3, wherein the one to three OADs are selected from the group consisting of metformin, sulfonylureas, dipeptidyl-peptidase-4 (DPP-4) inhibitors, glinides, or combinations thereof.

Details for Patent 10,434,147

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	April 20, 2000	10,434,147	2037-07-11
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	April 25, 2007	10,434,147	2037-07-11
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	December 16, 2015	10,434,147	2037-07-11
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	November 15, 2019	10,434,147	2037-07-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.